Dear All,No one is safe until we’re all safe! In the 7 April 2025 newsletter on antibiotic access ("UNSLAP: You reach for the antibiotic … and it’s not there!"), Louise Norton-Smith and I concluded that we need to work to address all the elements of the long and delicate supply chain from manufacturing to local registration to bringing the tablet across the last mile to a patient. On that note, there’s significant update!Based on a presentation by GARDP’s Global Access Director, Jennifer Cohn, I wrote in a 25 Sep 2023 newsletter ("Manufacturing underpins both access and stewardship: Cefiderocol as a case study") about a project to expand antibiotic access in LMIC countries. Specifically, Shionogi & Co. Ltd., GARDP (Global Antibiotic R&D Partnership), CHAI (Clinton Health Access Initiative), and Orchid Pharma Ltd. are collaborating to expand access to a WHO AWaRe Reserve antibiotic, cefiderocol. Cefiderocol targets a number of Gram-negative WHO priority pathogens and is on the World Health Organization (WHO) Model List of Essential Medicines. Here’s what the project looks like: Now, 1.5 years later, the project partners have given an update via a 28 Mar 2025 webinar (YouTube replay):https://www.youtube.com/watch?v=ghk8d15VpOwHere are the key takeaways from the webinar:Cefiderocol is a fourth-generation cephalosporin with FDA indications for the treatment...